首页|和血柔肝方含药血清通过鞘氨醇激酶-1对肝星状细胞增殖与凋亡的作用

和血柔肝方含药血清通过鞘氨醇激酶-1对肝星状细胞增殖与凋亡的作用

扫码查看
目的:和血柔肝方(HXRGF)含药血清调节鞘氨醇激酶-1(SphK1)对肝星状细胞(HSC)增殖与凋亡的作用.方法:采用Resistin处理HSC-T6 细胞,建立纤维化HSC模型,采用LV-rSphK1-OE、LV-rSphk1-shRNA慢病毒方法构建SphK1 过表达、低表达稳转细胞株,运用实时定量PCR、WB检测TGF-β、α-SMA、Col I、FN、Smad、SphK1mRNA及蛋白的表达、CCK8 实验检测细胞活力、AnnexinV-APC/7-AAD流式细胞学检测细胞凋亡情况.结果:与对照组比较,MF-HSC-T6 细胞中可见 TGF-β、α-SMA、Col I、FN、SphK1mRNA及蛋白表达水平升高,Smad mRNA水平降低(P<0.01);HSC-T6 SphK1 过表达细胞株中SphK1 及相关纤维化标志物的表达水平升高(P<0.01);HSC-T6 SphK1 低表达细胞株中TGF-β、α-SMA、Col I、FN mRNA等纤维化相关标志物降低,Smad mRNA水平升高(P<0.01).与模型组比较,中药复方HXRGF含药血清干预后,可见MF-HSC T6 SphK1mRNA及蛋白表达水平降低,并同时伴有α-SMA、Col I、FN表达水平的下降(P<0.01),HSC细胞增殖率下降(110.85%);shRNA-SphK1 转染组细胞增殖率下降,凋亡率(12.14%)升高(P<0.01);HSC-T6 SphK1 低表达组细胞凋亡率(16.48%)升高(P<0.01).结论:SphK1 可作为肝纤维化潜在治疗靶点.HXRGF干预通过抑制SphK1 表达,下调TGF-β、α-SMA等促纤维化因子的表达水平,抑制活化的HSC增殖,诱导HSC凋亡,缓解肝纤维化.
Effect of medicated serum of Hexuerougan formula on regulates the proliferation and apoptosis of hepatic stellate cells through sphingosine kinase-1
Objective:Investigation of the effect of serum containing Hepatic Soften and Nourish Formula(HXRGF)on the regulation of sphingosine kinase-1(SphK1)in the proliferation and apoptosis of hepatic stellate cells(HSC).Methods:Resistin was applied to treat HSC-T6 cells with Resistin to establish a fibrotic HSC model,and LV-rSphK1-OE and LV-rSphK1-shRNA lentivirus methods to construct stable cell lines with overexpression or low expression of SphK1.The mrna and protein expressions of TGF-β,α-SMA,Col I,FN,Smad and SphK1 were detected by real-time quantitative PCR and Western blot.The cell viability was detected by CCK8 assay and apoptosis was detected by flow cytometry.Results:①Compared with the control group,TGF-β,α-SMA,Col I,FN,SphK1mRNA and protein expression levels were increased in MF-HSC-T6 cells,whil Smade mRNA levels were decreased(all P<0.01).The expression levels of SphK1 and related fibrosis markers were increased in HSC-T6 SphK1 overexpression cell lines(P<0.01).Fibrosis related markers such as TGF-β,α-SMA,Col I and FN mRNA were decreased in HSC-T6 SphK1 low expression cell lines,while Smad mRNA levels were increased(P<0.01).②Compared with model group,the mrna and protein expression levels of MF-HSC T6 SphK1 were decreased after the intervention of TCM compound HXRGF containing serum,along with the expression levels of α-SMA,Col I and FN(P<0.01),and the proliferation rate of HSC cells was decreased(110.85%).Cell proliferation rate decreased and apoptosis rate increased(12.14%)in shRNA-SphK1 transfection group(P<0.01).The apoptosis rate of low expression group of HSC-T6 SphK1 was increased(16.48%,P<0.01).Conclusion:SphK1 can be a potential therapeutic target for hepatic fibrosis.By inhibiting the expression of SphK1,HXRGF can down-regulate the expression level of TGF-β,α-SMA and other pro-fibrosis factors,inhibit the proliferation of activated HSC,induce the apoptosis of HSC,and alleviate liver fibrosis.

hepatic stellate cellsphingosine kinase-1Hexuerougan foumula

王燕、肖雄、马丽、蒲诗云

展开 >

成都中医药大学附属第五人民医院(四川 成都,611130)

中国科学院新疆理化技术研究所

中国科学院大学

肝星状细胞 鞘氨醇激酶-1 和血柔肝方

国家自然科学基金项目

81860808

2024

中西医结合肝病杂志
中国中西医结合学会,湖北中医学院

中西医结合肝病杂志

CSTPCD
影响因子:0.908
ISSN:1005-0264
年,卷(期):2024.34(10)